{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:58:28Z","timestamp":1790758708428,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pemetrexed is a folate analogue metabolic inhibitor for mammalian cells.\nPemetrexed is toxic to several cancer cells by interfering with their new biosynthesis of nucleotides,\nthus causing cell apoptosis. Presently, Pemetrexed is given to patients with Non-Small\nCell Lung Cancer (NSCLC).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This review focuses on the recent patents of Pemetrexed. This assessment includes patents\ngrouped in segments like crystalline form patent, composition related patents, product patents,\nas well as a method of treatment. The aim of this review is to simplify inventors with existing\npatents in a single place.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Data were searched from several available databases, including paid databases which include\nOrbit\u00ae and SciFinder\u00ae. Free databases include Worldwide Espacenet\u00ae (EPO), Patentscope\u00ae\n(WIPO), InPASS (Indian patent database) and Google Patents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Some new polymorph and composition-related inventions of Pemetrexed have been recently\npatented as its orange-book listed patents will soon expire in May 2022. Further, because of the\nproblem of oxidation through the development and continuing storage of Pemetrexed composition,\nseveral excipients are experimented with within these patents to stabilize the same. Nevertheless,\nthere is a need for further development of an improved composition of Pemetrexed with improved\ncharacteristics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Wide research has been conducted on different processes for preparing Pemetrexed\nand formulation thereof. Such type of active research may clear the track for the generic companies\nin the United States, producing the formulation at low prices and providing universal health care at\neconomical prices.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574892816666210120113256","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T09:45:39Z","timestamp":1611654339000},"page":"333-349","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pemetrexed \u2013 First-Line Therapy for Non-Squamous Non-Small Cell Lung Cancer: A Review of Patent Literature"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-2618","authenticated-orcid":true,"given":"Pratik Ashwinbhai","family":"Vora","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Parul University, Vadodara, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-278X","authenticated-orcid":true,"given":"Rakesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Parul University, Vadodara, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5401-3120","authenticated-orcid":true,"given":"Abhay","family":"Dharamsi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Parul University, Vadodara, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/190488","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/190488\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/190488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T13:58:01Z","timestamp":1635775081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/190488\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574892816666210120113256","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}